HCPCS Level II J2327: Intravenous Injection of Risankizumab-rzaa, 1 mg

HCPCS Level II code J2327 denotes a 1 mg intravenous injection of risankizumab-rzaa, a biologic indicated for immune-mediated conditions. This national-level billing identifier matters because it standardizes reporting and reimbursement for intravenous administration of a high-cost specialty biologic across care sites. Accurate use of J2327 ensures proper clinical documentation and payer adjudication for drug units administered.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of coding context, typical sites of service for infusion-based biologic delivery, and the elements that influence billing such as unitization and encounter documentation. The publication also outlines common policy considerations payers apply to specialty intravenous biologics, including medical necessity review and site-of-care distinctions.

The report provides benchmarks and interpretive guidance on how J2327 is used in claims line reporting, summarizes relevant recent payer policy activity where available, and situates the code within clinical workflows for infusion centers and hospital outpatient departments. Data not available in the input are noted where applicable.

Billing Code Overview

HCPCS Level II code J2327 represents an intravenous injection of risankizumab-rzaa, 1 mg. This code describes the drug formulation and unit of measure for administration of risankizumab-rzaa when delivered intravenously.

Service type: Intravenous biologic drug administration
Typical site of service: Infusion center, hospital outpatient department, or other clinical settings equipped for intravenous biologic administration

Clinical Context

A 45-year-old patient with moderate-to-severe plaque psoriasis presents to an outpatient infusion center for administration of intravenous risankizumab-rzaa, billed as J2327 (injection, risankizumab-rzaa, intravenous, 1 mg). The patient has been evaluated by a dermatologist and met clinical criteria for biologic therapy after inadequate response to topical agents and phototherapy. Pre-infusion workflows include verification of orders, allergy review, informed consent, baseline vital signs, and assessment for active infection or tuberculosis. The medication is prepared by pharmacy under aseptic technique and delivered for IV push or short infusion per facility protocol. During administration, nursing documents medication name, lot number, dose, route (intravenous), start and stop times, and patient tolerance. Post-administration monitoring for infusion-related reactions occurs for a defined observation period; adverse events and site-of-care specifics are documented. Billing captures the drug as J2327 per milligram with appropriate HCPCS modifiers applied when indicated, and diagnosis linkage to the treating dermatologist’s ICD-10 code for psoriasis or other covered indication.

Coding Specifications

Modifier	Description	When to Use
`JW`	Drug amount discarded/not administered	When part of the single-dose vial is discarded due to patient-specific dosing and the discarded amount is billable per payer rules

Taxonomy Code	Specialty	Notes
`207Q00000X`	Dermatology	Primary specialty prescribing and overseeing biologic therapy for psoriasis and other dermatologic indications
`207RC0000X`	Rheumatology	Management of psoriatic arthritis and systemic inflammatory diseases using biologics
`208000000X`	Allergy & Immunology	Evaluation and management of immune-mediated diseases treated with biologics
`363L00000X`	Infusion Therapy	Providers and facilities specializing in IV administration and monitoring
`261QP2300X`	Clinical Pharmacist	Medication management, dosing verification, and sterile preparation oversight

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`L40.0`	Psoriasis vulgaris	Primary indication for risankizumab therapy in patients with moderate-to-severe plaque psoriasis
`L40.5`	Arthropathic psoriasis	Relevant when psoriatic arthritis coexists and systemic biologic therapy is indicated
`L40.8`	Other psoriasis	Captures less common psoriasis subtypes that may be treated with biologics
`M07.0`	Distal interphalangeal psoriatic arthropathy	Specific psoriatic arthritis manifestations treated by rheumatology with biologics
`M07.3`	Psoriatic spondylitis	Axial involvement of psoriatic disease where systemic therapy may be required
`Z79.899`	Other long term (current) drug therapy	Used to indicate ongoing long-term biologic therapy in medical record for chronic management
`D86.9`	Sarcoidosis, unspecified	Occasionally an off-label or investigational context; any non-standard indication requires documentation and payer review

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`96365`	Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour	Used when the administration of the biologic requires an initial IV infusion encounter and time-based billing is applicable
`96366`	Intravenous infusion, each additional hour (List separately in addition to code for primary infusion)	Used for extended infusion times beyond the first hour if clinically required
`96372`	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular	May be used when portions of biologic therapy are given subcutaneously in follow-up visits (note route difference)
`96413`	Chemotherapy administration, intravenous infusion technique, up to 1 hour, single or initial substance/drug	Sometimes used in infusion centers for complex biologic infusions subject to payer guidance; check payer-specific rules
`99070`	Supplies and materials (e.g., saline flushes, IV tubing)	Billed for non-drug supplies used during infusion when allowed by payer

OpenPayer

Summary & Overview